Stock CANF CAN-FITE BIOPHARMA LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Can-Fite BioPharma Ltd. Stock

Equities

CANF

IL0010944739

Pharmaceuticals

Market Closed - TEL AVIV STOCK EXCHANGE
Other stock markets
 07:24:54 2024-04-24 am EDT 		5-day change 1st Jan Change
2.6 ILa 0.00% Intraday chart for Can-Fite BioPharma Ltd. 0.00% 0.00%
Apr. 03 Can-Fite Biopharma Ltd. Announces Submission of an Investigational New Drug Application to the U.S. Food and Drug Administration for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis, Also Known as Non-Alcoholic Steatohepatitis, for the Company's Ongoing Phase IIb Clinical Study CI
Mar. 28 Can-Fite Biopharma Ltd. Announces Clinical Update CI

Financials

Sales 2024 * 800K 302M Sales 2025 * 800K 302M Capitalization 10.29M 3.89B
Net income 2024 * -6M -2.27B Net income 2025 * -7M -2.65B EV / Sales 2024 * 12.9 x
Net cash position 2024 * - 0 Net cash position 2025 * - 0 EV / Sales 2025 * 12.9 x
P/E ratio 2024 *
-
P/E ratio 2025 *
-
Employees 8
Yield 2024 *
-
Yield 2025 *
-
Free-Float 99.97%
More Fundamentals * Assessed data

Chart Can-Fite BioPharma Ltd.

Dynamic Chart

Latest news about Can-Fite BioPharma Ltd.

Can-Fite Biopharma Ltd. Announces Submission of an Investigational New Drug Application to the U.S. Food and Drug Administration for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis, Also Known as Non-Alcoholic Steatohepatitis, for the Company's Ongoing Phase IIb Clinical Study CI
Can-Fite Biopharma Ltd. Announces Clinical Update CI
Can-Fite BioPharma Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Can-Fite Biopharma Ltd. to Present Data from the Pancreatic and Liver Cancer Programs CI
Can-Fite BioPharma Ltd. Receives Notice of Allowance from the Canadian Intellectual Property Office CI
Can-Fite BioPharma Ltd. Expands the Out-Licensing Deal with Ewopharma to Include the Pancreatic Cancer Indication CI
Can-Fite Biopharma Ltd. Announces Results from Randomized Phase 3 Clinical Trial CI
Can-Fite BioPharma Ltd. Reports New Data on Namodenoson?s Anti-Obesity Mechanism of Action CI
Can-Fite Received FDA Positive Response to Psoriasis Pediatric Plan RE
Can-Fite BioPharma Ltd. Receives Positive Response from U.S. Food and Drug Administration on Pediatric Study Plan for Treatment of Children Suffering from Psoriasis with Piclidenoson CI
Can-Fite BioPharma Ltd. Completes the Design of a Phase IIa Study Protocol for the Treatment of Pancreatic Cancer Patients CI
Can-Fite BioPharma Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023 CI
Sector Update: Health Care Stocks Higher Late Tuesday Afternoon MT
Top Midday Gainers MT
Can-Fite Biopharma Reports 'Complete Response' in Liver Cancer Patient Treated With Namodenoson MT
More news

Analyst Recommendations on Can-Fite BioPharma Ltd.

HC Wainwright Adjusts Can-Fite Biopharma Price Target to $18 From $34, Maintains Buy Rating MT
CAN FITE BIOPHARMA : Aegis Capital Starts Can-Fite Biopharma at Buy with $5 Price Target MT
DJ Industrial : Wall Street Narrowly Mixed; Data, Fed Rate Meeting in Focus MT
More recommendations

Press releases Can-Fite BioPharma Ltd.

CAN-FITE, SCIENTIFIC ARTICLE PUBLISHED BY KOL PRESENTS NAMODENOSON AS A PROMISING DRUG CANDIDATE TO TREAT ADVANCED LIVER CANCER AND MASH AQ
Can-Fite: Scientific Article Published by KOL Presents Namodenoson as a Promising Drug Candidate to Treat Advanced Liver Cancer and MASH BU
Can Fite BioPharma : Scientific Article Published by KOL Presents Namodenoson as a Promising Drug Candidate to Treat Advanced Liver Cancer and MASH PU
Can Fite BioPharma : Submits FDA with an IND Application to Conduct Phase IIb Clinical Trial of Namodenoson in MASH Patients PU
Can-Fite: Submits FDA with an IND Application to Conduct Phase IIb Clinical Trial of Namodenoson in MASH Patients BU
More press releases

Quotes and Performance

Current month-7.14%
1 month-7.14%
More quotes

Highs and lows

1 week
2.50
Extreme 2.5
2.70
1 month
2.50
Extreme 2.5
3.00
Current year
2.50
Extreme 2.5
3.00
1 year
2.10
Extreme 2.1
4.10
3 years
2.10
Extreme 2.1
31.10
5 years
2.10
Extreme 2.1
112.00
10 years
2.10
Extreme 2.1
1 163.00
More quotes

Managers and Directors - Can-Fite BioPharma Ltd.

Managers TitleAgeSince
Motti Farbstein CEO
 Chief Executive Officer 59 03-07-31
Pnina Fishman FOU
 Founder 74 94-09-10
Ilan Cohn FOU
 Founder 67 94-09-10
Members of the board TitleAgeSince
Abraham Sartani BRD
 Director/Board Member 76 00-12-31
Ilan Cohn FOU
 Founder 67 94-09-10
Pnina Fishman FOU
 Founder 74 94-09-10
More insiders

Quotes

Date Price Change Volume
24-04-24 2.6 0.00% 1,660,006
24-04-21 2.6 0.00% 10,389,500
24-04-18 2.6 0.00% 2,005,503
24-04-17 2.6 -3.70% 3,435,261
24-04-16 2.7 -3.57% 2,296,687

Delayed Quote TEL AVIV STOCK EXCHANGE, April 24, 2024 at 07:24 am EDT

More quotes

Company Profile

Can Fite Biofarma Ltd is an Israel-based clinical-stage biopharmaceutical company engaged in developing orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases and erectile dysfunction. The Company co-develop formulations of cannabis components for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases. It's technology utilizes the Gi protein associated A3AR as a therapeutic target. A3AR is expressed in inflammatory and cancer cells, and not significantly expressed in normal cells, suggesting that the receptor could be a target for pharmacological intervention.
Sector
Pharmaceuticals
Calendar
2024-05-01 - Planet MicroCap Showcase
More about the company

Income Statement Evolution

More financial data

Ratings for Can-Fite BioPharma Ltd.

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
0.026
Average target price
-
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Biopharmaceuticals

1st Jan change Capi.
CAN-FITE BIOPHARMA LTD. Stock Can-Fite BioPharma Ltd.
0.00% 10.3M
CSL LIMITED Stock CSL Limited
-2.86% 87.37B
SAMSUNG BIOLOGICS CO.,LTD. Stock Samsung Biologics Co.,Ltd.
+3.95% 41.01B
BIOGEN INC. Stock Biogen Inc.
-21.94% 28.08B
UCB Stock UCB
+53.11% 24.72B
BIOMARIN PHARMACEUTICAL INC. Stock BioMarin Pharmaceutical Inc.
-5.41% 17.47B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD. Stock Chongqing Zhifei Biological Products Co., Ltd.
-44.23% 11.69B
INCYTE CORPORATION Stock Incyte Corporation
-17.60% 11.6B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD. Stock Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.
-13.96% 11.56B
SWEDISH ORPHAN BIOVITRUM AB Stock Swedish Orphan Biovitrum AB
-0.22% 8.44B
Biopharmaceuticals
  1. Stock Market
  2. Equities
  3. CANF Stock